Second-line triple therapy in failures with vonoprazan-based triple therapy for eradication of Helicobacter pylori
Gastric acid inhibition during treatment is important for the eradication of ( ) infection. A novel potassium-competitive acid blocker, vonoprazan (VPZ), has been demonstrated to achieve high eradication rates; however, the efficacy of second-line treatment in failures of VPZ-based triple therapy ha...
Gespeichert in:
| Veröffentlicht in: | Biomedical reports 2018-08, Vol.9 (2), p.169-174 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 174 |
|---|---|
| container_issue | 2 |
| container_start_page | 169 |
| container_title | Biomedical reports |
| container_volume | 9 |
| creator | Mori, Naoyoshi Nishiura, Yuuki Suga, Daisuke Moritani, Isao Yamanaka, Yutaka Ooya, Yumi Inoue, Hidekazu Takase, Koujirou Hioki, Masato Shiraki, Katsuya |
| description | Gastric acid inhibition during treatment is important for the eradication of
(
) infection. A novel potassium-competitive acid blocker, vonoprazan (VPZ), has been demonstrated to achieve high eradication rates; however, the efficacy of second-line treatment in failures of VPZ-based triple therapy has not been well studied. The aim of the current study was to determine the efficacy of VPZ in a first-line regimen for
eradication, and the efficacy of a second-line regimen using metronidazole (MTZ) in failures with the first-line regimen. Of 580 subjects enrolled in the study, 524 patients completed first-line treatment (275 patients who received VPZ and 249 patients who received LPZ). First-line regimens consisted of a combination of clarithromycin (CAM) 200 or 400 mg twice a day, amoxicillin (AMPC) 750 mg twice a day, and either LPZ 30 mg or VPZ 20 mg twice a day, administered orally for 7 days. CAM and VPZ/LPZ were replaced with metronidazole (MTZ) 250 mg and rabeprazole 10 mg in the second-line regimens. The eradication of
was assessed by the
stool antigen test. The overall first-line eradication rate with VPZ was significantly higher than that with LPZ [91.0% (250/275) vs. 84.7% (211/249), respectively, P=0.030]. The dose of CAM (400 vs. 800 mg) did not affect the eradication rate in either the VPZ or LPZ regimens. The overall eradication rates of the second-line regimens with MTZ did not differ significantly between the VPZ-failure and LPZ-failure groups [87.0% (20/23) vs. 87.9% (29/33), respectively, P=0.700]. Therefore, VPZ was significantly more effective than LPZ for first-line treatment. In patients with failure of first-line eradication therapy, successful results of second-line eradication therapy did not differ between the VPZ- and LPZ-failure groups. In conclusion, VPZ-based triple therapy should be recommended for eradication of
. |
| doi_str_mv | 10.3892/br.2018.1111 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6036823</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A553761011</galeid><sourcerecordid>A553761011</sourcerecordid><originalsourceid>FETCH-LOGICAL-c479t-c69741fa67c1fb60dc2e31d685f197961a68085dfcdbbfc4d10de32fb7ff753</originalsourceid><addsrcrecordid>eNptks9LHTEQx5fSUsV681wWeunBfebHbrK5FERqLQge9B7yY-KL5CXbZNfy-tc3D-1DpZPDDMlnvmGGb9OcYLSioyBnOq8IwuMK13jXHBLUi070PXm_r2l_0ByX8oBqCI7IMH5sDihCmHIuDpt8CyZF2wUfoZ2zn0JNa8hq2rY-tk75sGQo7W8_r9vHFNOU1R8VO60K2LcNLuW2VtYbNfsU2-TaKwjeJK3MDLmdtiFl_6n54FQocPycj5rby-93F1fd9c2Pnxfn153puZg7wwTvsVOMG-w0Q9YQoNiycXBYcMGwYiMaB-uM1dqZ3mJkgRKnuXN8oEfNtyfVadEbsAbinFWQU_YblbcyKS9fv0S_lvfpUTJE2UhoFfj6LJDTrwXKLDe-GAhBRUhLkQRxPPCeUlTRL2_Qh7TkWIerlBBk5Iy_oO5VAOmjS_VfsxOV58NAOcMI40qt_kPVY2FTNxnB-Xr_quH0qcHkVEoGt58RI7kzidRZ7kwidyap-OeXe9nD_yxB_wIO97jc</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2099287670</pqid></control><display><type>article</type><title>Second-line triple therapy in failures with vonoprazan-based triple therapy for eradication of Helicobacter pylori</title><source>Spandidos Publications Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><creator>Mori, Naoyoshi ; Nishiura, Yuuki ; Suga, Daisuke ; Moritani, Isao ; Yamanaka, Yutaka ; Ooya, Yumi ; Inoue, Hidekazu ; Takase, Koujirou ; Hioki, Masato ; Shiraki, Katsuya</creator><creatorcontrib>Mori, Naoyoshi ; Nishiura, Yuuki ; Suga, Daisuke ; Moritani, Isao ; Yamanaka, Yutaka ; Ooya, Yumi ; Inoue, Hidekazu ; Takase, Koujirou ; Hioki, Masato ; Shiraki, Katsuya</creatorcontrib><description>Gastric acid inhibition during treatment is important for the eradication of
(
) infection. A novel potassium-competitive acid blocker, vonoprazan (VPZ), has been demonstrated to achieve high eradication rates; however, the efficacy of second-line treatment in failures of VPZ-based triple therapy has not been well studied. The aim of the current study was to determine the efficacy of VPZ in a first-line regimen for
eradication, and the efficacy of a second-line regimen using metronidazole (MTZ) in failures with the first-line regimen. Of 580 subjects enrolled in the study, 524 patients completed first-line treatment (275 patients who received VPZ and 249 patients who received LPZ). First-line regimens consisted of a combination of clarithromycin (CAM) 200 or 400 mg twice a day, amoxicillin (AMPC) 750 mg twice a day, and either LPZ 30 mg or VPZ 20 mg twice a day, administered orally for 7 days. CAM and VPZ/LPZ were replaced with metronidazole (MTZ) 250 mg and rabeprazole 10 mg in the second-line regimens. The eradication of
was assessed by the
stool antigen test. The overall first-line eradication rate with VPZ was significantly higher than that with LPZ [91.0% (250/275) vs. 84.7% (211/249), respectively, P=0.030]. The dose of CAM (400 vs. 800 mg) did not affect the eradication rate in either the VPZ or LPZ regimens. The overall eradication rates of the second-line regimens with MTZ did not differ significantly between the VPZ-failure and LPZ-failure groups [87.0% (20/23) vs. 87.9% (29/33), respectively, P=0.700]. Therefore, VPZ was significantly more effective than LPZ for first-line treatment. In patients with failure of first-line eradication therapy, successful results of second-line eradication therapy did not differ between the VPZ- and LPZ-failure groups. In conclusion, VPZ-based triple therapy should be recommended for eradication of
.</description><identifier>ISSN: 2049-9434</identifier><identifier>EISSN: 2049-9442</identifier><identifier>DOI: 10.3892/br.2018.1111</identifier><identifier>PMID: 30013779</identifier><language>eng</language><publisher>England: Spandidos Publications</publisher><subject>Acids ; Amoxicillin ; Antibiotics ; Antigens ; Antimicrobial agents ; Care and treatment ; Clarithromycin ; Data analysis ; Effectiveness ; Endoscopy ; Eradication ; Failure ; Gastric acid ; Gastric cancer ; Gastric juice ; Health aspects ; Helicobacter infections ; Helicobacter pylori ; Infections ; Metronidazole ; Patients ; Potassium ; Risk factors ; Therapy</subject><ispartof>Biomedical reports, 2018-08, Vol.9 (2), p.169-174</ispartof><rights>COPYRIGHT 2018 Spandidos Publications</rights><rights>Copyright Spandidos Publications UK Ltd. 2018</rights><rights>Copyright © 2018, Spandidos Publications 2018</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c479t-c69741fa67c1fb60dc2e31d685f197961a68085dfcdbbfc4d10de32fb7ff753</citedby><cites>FETCH-LOGICAL-c479t-c69741fa67c1fb60dc2e31d685f197961a68085dfcdbbfc4d10de32fb7ff753</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6036823/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6036823/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30013779$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Mori, Naoyoshi</creatorcontrib><creatorcontrib>Nishiura, Yuuki</creatorcontrib><creatorcontrib>Suga, Daisuke</creatorcontrib><creatorcontrib>Moritani, Isao</creatorcontrib><creatorcontrib>Yamanaka, Yutaka</creatorcontrib><creatorcontrib>Ooya, Yumi</creatorcontrib><creatorcontrib>Inoue, Hidekazu</creatorcontrib><creatorcontrib>Takase, Koujirou</creatorcontrib><creatorcontrib>Hioki, Masato</creatorcontrib><creatorcontrib>Shiraki, Katsuya</creatorcontrib><title>Second-line triple therapy in failures with vonoprazan-based triple therapy for eradication of Helicobacter pylori</title><title>Biomedical reports</title><addtitle>Biomed Rep</addtitle><description>Gastric acid inhibition during treatment is important for the eradication of
(
) infection. A novel potassium-competitive acid blocker, vonoprazan (VPZ), has been demonstrated to achieve high eradication rates; however, the efficacy of second-line treatment in failures of VPZ-based triple therapy has not been well studied. The aim of the current study was to determine the efficacy of VPZ in a first-line regimen for
eradication, and the efficacy of a second-line regimen using metronidazole (MTZ) in failures with the first-line regimen. Of 580 subjects enrolled in the study, 524 patients completed first-line treatment (275 patients who received VPZ and 249 patients who received LPZ). First-line regimens consisted of a combination of clarithromycin (CAM) 200 or 400 mg twice a day, amoxicillin (AMPC) 750 mg twice a day, and either LPZ 30 mg or VPZ 20 mg twice a day, administered orally for 7 days. CAM and VPZ/LPZ were replaced with metronidazole (MTZ) 250 mg and rabeprazole 10 mg in the second-line regimens. The eradication of
was assessed by the
stool antigen test. The overall first-line eradication rate with VPZ was significantly higher than that with LPZ [91.0% (250/275) vs. 84.7% (211/249), respectively, P=0.030]. The dose of CAM (400 vs. 800 mg) did not affect the eradication rate in either the VPZ or LPZ regimens. The overall eradication rates of the second-line regimens with MTZ did not differ significantly between the VPZ-failure and LPZ-failure groups [87.0% (20/23) vs. 87.9% (29/33), respectively, P=0.700]. Therefore, VPZ was significantly more effective than LPZ for first-line treatment. In patients with failure of first-line eradication therapy, successful results of second-line eradication therapy did not differ between the VPZ- and LPZ-failure groups. In conclusion, VPZ-based triple therapy should be recommended for eradication of
.</description><subject>Acids</subject><subject>Amoxicillin</subject><subject>Antibiotics</subject><subject>Antigens</subject><subject>Antimicrobial agents</subject><subject>Care and treatment</subject><subject>Clarithromycin</subject><subject>Data analysis</subject><subject>Effectiveness</subject><subject>Endoscopy</subject><subject>Eradication</subject><subject>Failure</subject><subject>Gastric acid</subject><subject>Gastric cancer</subject><subject>Gastric juice</subject><subject>Health aspects</subject><subject>Helicobacter infections</subject><subject>Helicobacter pylori</subject><subject>Infections</subject><subject>Metronidazole</subject><subject>Patients</subject><subject>Potassium</subject><subject>Risk factors</subject><subject>Therapy</subject><issn>2049-9434</issn><issn>2049-9442</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNptks9LHTEQx5fSUsV681wWeunBfebHbrK5FERqLQge9B7yY-KL5CXbZNfy-tc3D-1DpZPDDMlnvmGGb9OcYLSioyBnOq8IwuMK13jXHBLUi070PXm_r2l_0ByX8oBqCI7IMH5sDihCmHIuDpt8CyZF2wUfoZ2zn0JNa8hq2rY-tk75sGQo7W8_r9vHFNOU1R8VO60K2LcNLuW2VtYbNfsU2-TaKwjeJK3MDLmdtiFl_6n54FQocPycj5rby-93F1fd9c2Pnxfn153puZg7wwTvsVOMG-w0Q9YQoNiycXBYcMGwYiMaB-uM1dqZ3mJkgRKnuXN8oEfNtyfVadEbsAbinFWQU_YblbcyKS9fv0S_lvfpUTJE2UhoFfj6LJDTrwXKLDe-GAhBRUhLkQRxPPCeUlTRL2_Qh7TkWIerlBBk5Iy_oO5VAOmjS_VfsxOV58NAOcMI40qt_kPVY2FTNxnB-Xr_quH0qcHkVEoGt58RI7kzidRZ7kwidyap-OeXe9nD_yxB_wIO97jc</recordid><startdate>20180801</startdate><enddate>20180801</enddate><creator>Mori, Naoyoshi</creator><creator>Nishiura, Yuuki</creator><creator>Suga, Daisuke</creator><creator>Moritani, Isao</creator><creator>Yamanaka, Yutaka</creator><creator>Ooya, Yumi</creator><creator>Inoue, Hidekazu</creator><creator>Takase, Koujirou</creator><creator>Hioki, Masato</creator><creator>Shiraki, Katsuya</creator><general>Spandidos Publications</general><general>Spandidos Publications UK Ltd</general><general>D.A. Spandidos</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>LK8</scope><scope>M7P</scope><scope>P5Z</scope><scope>P62</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20180801</creationdate><title>Second-line triple therapy in failures with vonoprazan-based triple therapy for eradication of Helicobacter pylori</title><author>Mori, Naoyoshi ; Nishiura, Yuuki ; Suga, Daisuke ; Moritani, Isao ; Yamanaka, Yutaka ; Ooya, Yumi ; Inoue, Hidekazu ; Takase, Koujirou ; Hioki, Masato ; Shiraki, Katsuya</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c479t-c69741fa67c1fb60dc2e31d685f197961a68085dfcdbbfc4d10de32fb7ff753</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Acids</topic><topic>Amoxicillin</topic><topic>Antibiotics</topic><topic>Antigens</topic><topic>Antimicrobial agents</topic><topic>Care and treatment</topic><topic>Clarithromycin</topic><topic>Data analysis</topic><topic>Effectiveness</topic><topic>Endoscopy</topic><topic>Eradication</topic><topic>Failure</topic><topic>Gastric acid</topic><topic>Gastric cancer</topic><topic>Gastric juice</topic><topic>Health aspects</topic><topic>Helicobacter infections</topic><topic>Helicobacter pylori</topic><topic>Infections</topic><topic>Metronidazole</topic><topic>Patients</topic><topic>Potassium</topic><topic>Risk factors</topic><topic>Therapy</topic><toplevel>online_resources</toplevel><creatorcontrib>Mori, Naoyoshi</creatorcontrib><creatorcontrib>Nishiura, Yuuki</creatorcontrib><creatorcontrib>Suga, Daisuke</creatorcontrib><creatorcontrib>Moritani, Isao</creatorcontrib><creatorcontrib>Yamanaka, Yutaka</creatorcontrib><creatorcontrib>Ooya, Yumi</creatorcontrib><creatorcontrib>Inoue, Hidekazu</creatorcontrib><creatorcontrib>Takase, Koujirou</creatorcontrib><creatorcontrib>Hioki, Masato</creatorcontrib><creatorcontrib>Shiraki, Katsuya</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest Central UK/Ireland</collection><collection>Advanced Technologies & Aerospace Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Biological Science Database</collection><collection>Advanced Technologies & Aerospace Database</collection><collection>ProQuest Advanced Technologies & Aerospace Collection</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Biomedical reports</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mori, Naoyoshi</au><au>Nishiura, Yuuki</au><au>Suga, Daisuke</au><au>Moritani, Isao</au><au>Yamanaka, Yutaka</au><au>Ooya, Yumi</au><au>Inoue, Hidekazu</au><au>Takase, Koujirou</au><au>Hioki, Masato</au><au>Shiraki, Katsuya</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Second-line triple therapy in failures with vonoprazan-based triple therapy for eradication of Helicobacter pylori</atitle><jtitle>Biomedical reports</jtitle><addtitle>Biomed Rep</addtitle><date>2018-08-01</date><risdate>2018</risdate><volume>9</volume><issue>2</issue><spage>169</spage><epage>174</epage><pages>169-174</pages><issn>2049-9434</issn><eissn>2049-9442</eissn><abstract>Gastric acid inhibition during treatment is important for the eradication of
(
) infection. A novel potassium-competitive acid blocker, vonoprazan (VPZ), has been demonstrated to achieve high eradication rates; however, the efficacy of second-line treatment in failures of VPZ-based triple therapy has not been well studied. The aim of the current study was to determine the efficacy of VPZ in a first-line regimen for
eradication, and the efficacy of a second-line regimen using metronidazole (MTZ) in failures with the first-line regimen. Of 580 subjects enrolled in the study, 524 patients completed first-line treatment (275 patients who received VPZ and 249 patients who received LPZ). First-line regimens consisted of a combination of clarithromycin (CAM) 200 or 400 mg twice a day, amoxicillin (AMPC) 750 mg twice a day, and either LPZ 30 mg or VPZ 20 mg twice a day, administered orally for 7 days. CAM and VPZ/LPZ were replaced with metronidazole (MTZ) 250 mg and rabeprazole 10 mg in the second-line regimens. The eradication of
was assessed by the
stool antigen test. The overall first-line eradication rate with VPZ was significantly higher than that with LPZ [91.0% (250/275) vs. 84.7% (211/249), respectively, P=0.030]. The dose of CAM (400 vs. 800 mg) did not affect the eradication rate in either the VPZ or LPZ regimens. The overall eradication rates of the second-line regimens with MTZ did not differ significantly between the VPZ-failure and LPZ-failure groups [87.0% (20/23) vs. 87.9% (29/33), respectively, P=0.700]. Therefore, VPZ was significantly more effective than LPZ for first-line treatment. In patients with failure of first-line eradication therapy, successful results of second-line eradication therapy did not differ between the VPZ- and LPZ-failure groups. In conclusion, VPZ-based triple therapy should be recommended for eradication of
.</abstract><cop>England</cop><pub>Spandidos Publications</pub><pmid>30013779</pmid><doi>10.3892/br.2018.1111</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2049-9434 |
| ispartof | Biomedical reports, 2018-08, Vol.9 (2), p.169-174 |
| issn | 2049-9434 2049-9442 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6036823 |
| source | Spandidos Publications Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central |
| subjects | Acids Amoxicillin Antibiotics Antigens Antimicrobial agents Care and treatment Clarithromycin Data analysis Effectiveness Endoscopy Eradication Failure Gastric acid Gastric cancer Gastric juice Health aspects Helicobacter infections Helicobacter pylori Infections Metronidazole Patients Potassium Risk factors Therapy |
| title | Second-line triple therapy in failures with vonoprazan-based triple therapy for eradication of Helicobacter pylori |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T12%3A30%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Second-line%20triple%20therapy%20in%20failures%20with%20vonoprazan-based%20triple%20therapy%20for%20eradication%20of%20Helicobacter%20pylori&rft.jtitle=Biomedical%20reports&rft.au=Mori,%20Naoyoshi&rft.date=2018-08-01&rft.volume=9&rft.issue=2&rft.spage=169&rft.epage=174&rft.pages=169-174&rft.issn=2049-9434&rft.eissn=2049-9442&rft_id=info:doi/10.3892/br.2018.1111&rft_dat=%3Cgale_pubme%3EA553761011%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2099287670&rft_id=info:pmid/30013779&rft_galeid=A553761011&rfr_iscdi=true |